MedTrace Logo

Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

NCT04461795 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-04-13

Study results available
· View outcomes & findings →

Summary

This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.

Conditions

Interventions

DRUG

Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]

225 MG/1.5 ML Subcutaneous Solution

Sponsors & Collaborators

  • David True

    lead INDUSTRY

Principal Investigators

  • David True · Clinvest Research

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-01-10
Completion
2022-01-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04461795 on ClinicalTrials.gov